Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

Dementia: A National Crisis – a review of the Manchester 2012 conference

It was clear from the title – Dementia: A National Crisis – that the conference would focus on the important challenges facing many people living with dementia in the country today.

24 Oct 2012

Antipsychotic drug quandary for Alzheimer’s patients

Stopping treatment with risperidone to limit side effects risks the return of psychosis or agitation in patients with Alzheimer’s disease who have been taking the drug to suppress such symptoms, research shows.

23 Oct 2012

Study still implicates amyloid beta in causing Alzheimer's dementia

Researchers at Washington University School of Medicine in St. Louis have found a key difference in the brains of people with Alzheimer's disease and those who are cognitively normal but still have brain plaques that characterize this type of dementia.

23 Oct 2012

Blood-circulating monocytes can replace brain resident microglia

The immune system is comprised of multiple cell types each capable of specialized functions to protect the body from invading pathogens and promote tissue repair after injury. One cell type, known as monocytes, circulates throughout the organism in the blood and enters tissues to actively phagocytose (eat!) foreign cells and assist in tissue healing.

23 Oct 2012

CSF biomarkers can differentiate patients with Alzheimer's or Parkinson disease

Analysis of specific biomarkers in a cerebrospinal fluid sample can differentiate patients with Alzheimer's disease from those with other types of dementia. The method, which is being studied by researchers at Sahlgrenska Academy, may eventually permit earlier detection of Alzheimer's disease.

23 Oct 2012

New data on Posiphen for Alzheimer's disease treatment to be presented at Biotech Symposium

QR Pharma, Inc., a clinical stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative disorders, announced today that Dr. Maria Maccecchini, CEO, will be presenting new data on its lead compound "Posiphen® Recovers Memory, Learning and Brain Function in Alzheimer Transgenic Mice" at the 12th Annual Biotech Symposium, taking place October 22, 2012 in Philadelphia, PA.

22 Oct 2012

Analysis of Cerebrospinal Fluid Biomarkers may help early detection of Alzheimer´S Disease

22 Oct 2012

VEGF produced by NPCs plays a strong role in influencing microglial behavior

The brain's key "breeder" cells, it turns out, do more than that. They secrete substances that boost the numbers and strength of critical brain-based immune cells believed to play a vital role in brain health. This finding adds a new dimension to our understanding of how resident stem cells and stem cell transplants may improve brain function.

22 Oct 2012

Leaders come together to discuss latest advances in neurosciences

Stony Brook Medicine's Neurosciences Institute brings together leaders in the field of neurosciences to present the latest advances in research and clinical care for neurodegenerative disorders, neuropsychiatric disorders, and neuro-ophthalmology.

20 Oct 2012

Research roundup: Financial impact of reducing surgical complications; Pay for performance to doctors, hospitals yields mixed results

The authors write: "We found that if a hospital's surgical inpatient volume is not growing, such a program results in negative cash flow. We also found that if a hospital's surgical volume is growing, and if the hospital can sufficiently reduce the average length-of-stay for surgical patients without complications, the cash flow could be positive. We recommend that hospitals with limited growth prospects that are nonetheless contemplating a surgical complication reduction program establish agreements with payers to share in any savings generated by the program."

20 Oct 2012

Shunting may not ward off poor hydrocephalus cognitive outcomes

Around half of patients with idiopathic normal-pressure hydrocephalus will develop dementia, despite responding to shunting, study findings suggest.

19 Oct 2012

Antidepressant use may increase risk of strokes caused by bleeding in the brain

Research shows that use of popular antidepressants is linked to an increased risk of some strokes caused by bleeding in the brain, but that the risk is low, according to a multi-study analysis published in the October 17, 2012, online issue of Neurology®, the medical journal of the American Academy of Neurology.

19 Oct 2012

Neuralstem initiates second cohort NSI-189 Phase Ib trial in major depressive disorder

Neuralstem, Inc. announced that it has begun dosing the second cohort of patients in its ongoing Phase Ib to test the safety of NSI-189 in the treatment of major depressive disorder (MDD).

19 Oct 2012

High-carb diet may increase risk of mild cognitive impairment among older people

People 70 and older who eat food high in carbohydrates have nearly four times the risk of developing mild cognitive impairment, and the danger also rises with a diet heavy in sugar, Mayo Clinic researchers have found.

17 Oct 2012

New findings on sleep deprivation presented at Neuroscience 2012

New findings presented today report the important role sleep plays, and the brain mechanisms at work as sleep shapes memory, learning, and behavior. The findings were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

17 Oct 2012

Animal research shows promise in treating AD, brain damage and heart problems resulting from SCIs

New animal studies provide additional support for investigating stem cell treatments for Parkinson's disease, head trauma, and dangerous heart problems that accompany spinal cord injury, according to research findings released today.

16 Oct 2012

New findings on Alzheimer's disease presented at Neuroscience 2012

Curtailing the imminent rise in Alzheimer's disease (AD) will require early, accurate diagnostic tests and treatments, and researchers are closer to achieving these two goals. New findings in medical imaging, molecular analysis of neurological diseases, and development of treatments using mouse models were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Oct 2012

Embryonic neuron transplants could effectively treat brain diseases

The unexpected survival of embryonic neurons transplanted into the brains of newborn mice in a series of experiments at the University of California, San Francisco (UCSF) raises hope for the possibility of using neuronal transplantation to treat diseases like Alzheimer's, epilepsy, Huntington's, Parkinson's and schizophrenia.

15 Oct 2012

AAPS recognizes top scientists in pharmaceutical sciences

During the Opening Session of the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, AAPS President David Y. Mitchell, Ph.D., presented the following ground-breaking researchers with awards commemorating their contributions to the pharmaceutical sciences:

15 Oct 2012

Highlights of Mount Sinai research at Neuroscience 2012

Researchers from Mount Sinai School of Medicine are presenting important discoveries on the involvement of the immune system and dopamine cells in the onset of depression at Neuroscience 2012, the Society for Neuroscience's 42nd annual meeting on October 13 -17 in New Orleans, and are available for interviews.

15 Oct 2012